519.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$517.72
Offen:
$520.79
24-Stunden-Volumen:
1.07M
Relative Volume:
0.60
Marktkapitalisierung:
$196.14B
Einnahmen:
$42.88B
Nettoeinkommen (Verlust:
$6.34B
KGV:
31.45
EPS:
16.53
Netto-Cashflow:
$7.27B
1W Leistung:
+0.06%
1M Leistung:
-2.92%
6M Leistung:
-15.03%
1J Leistung:
-10.84%
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TMO
Thermo Fisher Scientific Inc
|
519.90 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
![]()
DHR
Danaher Corp
|
212.80 | 152.09B | 23.88B | 3.90B | 5.30B | 5.28 |
![]()
A
Agilent Technologies Inc
|
121.97 | 34.79B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IDXX
Idexx Laboratories Inc
|
423.60 | 34.45B | 3.90B | 887.87M | 798.08M | 10.67 |
![]()
IQV
Iqvia Holdings Inc
|
186.11 | 32.81B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
2024-10-01 | Eingeleitet | Stephens | Overweight |
2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
2024-06-03 | Fortgesetzt | Jefferies | Buy |
2024-03-18 | Fortgesetzt | Citigroup | Neutral |
2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2023-12-18 | Eingeleitet | HSBC Securities | Buy |
2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2023-09-28 | Eingeleitet | Bernstein | Outperform |
2023-09-06 | Fortgesetzt | Citigroup | Buy |
2023-07-19 | Eingeleitet | Raymond James | Outperform |
2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
2023-04-04 | Bestätigt | Barclays | Overweight |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2022-01-26 | Fortgesetzt | Barclays | Overweight |
2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
2021-10-15 | Fortgesetzt | Cowen | Outperform |
2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-03 | Eingeleitet | Barclays | Overweight |
2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
2020-12-02 | Eingeleitet | Goldman | Buy |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
2020-07-07 | Bestätigt | Needham | Buy |
2020-04-23 | Bestätigt | Needham | Buy |
2020-01-31 | Bestätigt | Needham | Buy |
2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
2020-01-07 | Eingeleitet | Citigroup | Buy |
2019-11-15 | Eingeleitet | Stifel | Buy |
2019-07-25 | Bestätigt | Needham | Buy |
2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
2019-05-23 | Bestätigt | Needham | Strong Buy |
2019-04-22 | Bestätigt | Needham | Strong Buy |
2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Is Thermo Fisher Scientific Inc. (TMO) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Thermo Fisher takes No. 1 spot on WNY life science list for first time - The Business Journals
High Content Screening/Imaging Market Analysis 2025-2029: Increasing R&D Budgets, Emerging Economies and Technological Advances Fueling Opportunities - GlobeNewswire Inc.
Is Thermo Fisher Scientific Inc. (TMO) The Best Healthcare Dividend Stock to Invest in? - MSN
Cell Line Development Market is Expected to Grow at a CAGR - openPR
Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis - MSN
Precision Oncology Market Top Companies StudyThermo Fisher - openPR
Gamma Ray Spectroscopy Market Is Booming Worldwide 2025-2032 | - openPR
Thermo Fisher Scientific (TMO) Fell as Expectations for Demand Recovery in 2025 Continue to Moderate - MSN
Genetic Toxicology Testing Market Is Booming Worldwide | Thermo - openPR
Life Science Instrumentation Market Demand, Growth and Future - openPR
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab - Yahoo Finance
GMP Cell Therapy Consumables Market Deep Research 2025-2032 | - openPR
South East Asia And South Asia Industrial Microbiology Market - openPR
Proteinase K Market Future Business Opportunities 2025-2032 | Thermo Fisher Scientific Inc., Merck KGaA, Qiagen N.V. - openPR
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today - Benzinga
Thermo Fisher Scientific Thrives Amid Diabetes Market Expansion - Zenopa
Bioreactors Market to Witness Remarkable Growth with Thermo Fisher Scientific, Inc., Merck KGaA - openPR
Pharmacogenomics Market Growth and Future Scope 2025-2032 | - openPR
Thermo Fisher Scientific's $4B Filtration Acquisition & - openPR
The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP - Yahoo Finance
DNA Sequencing Market Detailed In New Research Report 2025 | - openPR
Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific - MSN
Thermo Fisher Scientific (TMO): One of the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Thermo Fisher Scientific (NYSE:TMO) Advances Semiconductor Manufacturing With New Automated Lab Solution - Yahoo Finance
Biomedical Refrigerators Market to Witness Remarkable Growth with Thermo Fisher Scientific, Aegis Scientific, Inc. - openPR
Helicobacter Pylori Diagnostic Market Top Companies Study - openPR
Is Thermo Fisher Scientific Inc. (TMO) the Best Strong Buy Stock to Buy Right Now? - Insider Monkey
Biotechnology Reagents and Kits Market A Comprehensive Study - openPR
Gas Chromatography Market Is Booming Worldwide 2025-2032 | - openPR
Thermo Fisher Scientific debuts Transcend VTLX-1 UHPLC system for automated sample preparation - R&D World
$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today - Benzinga
Is the Market Bullish or Bearish on Thermo Fisher Scientific? - Benzinga
Senior VP & General Counsel Michael Boxer Sold A Bunch Of Shares In Thermo Fisher Scientific - Simply Wall St
HSBC Adjusts Price Target on Thermo Fisher Scientific to $670 From $700, Keeps Buy Rating - Marketscreener.com
Faces of HR: Thermo Fisher Scientific's Pallavi Srivastava on the importance of fungibility of skills within the workforce - Human Resources Online
New exhibit at Discovery Center showcases lab techniques for kids - MyStateline.com
Market Whales and Their Recent Bets on TMO Options - Benzinga
CRDMO Market Research 2025: A Highly Competitive $328 - GlobeNewswire
Exosomes Drug Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne - openPR
Thermo Fisher Scientific’s CHF1.425 Billion Bond Issuance - Global Legal Chronicle
Laboratory Equipment and Disposables Market is expected - openPR
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
Thermo Fisher Executive Cashes In on Stock Sale! - TipRanks
Thermo Fisher Scientific SVP sells $2.01 million in stock By Investing.com - Investing.com Australia
Thermo Fisher Scientific SVP sells $2.01 million in stock - Investing.com
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Neurological Biomarkers: Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of PerkinElmer, Abbott Labs, Thermo Fisher Scientific, Banyan Biomarkers, Bio-Rad Labs & More - Yahoo Finance
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mexico In-Vitro Diagnostics Market Deep Research 2025-2032 | Thermo Fisher Scientific Inc., Siemens Healthineers - openPR
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):